Citicoline & Alpha-GPC: Do the Focus Cholines Actually Work?

The VerdictLOW CONVICTION

The two cholines in every focus stack were tested on dementia patients, not healthy adults wanting focus.

Before you buy a "focus" supplement with citicoline or alpha-GPC, ask one question: am I a healthy adult who just wants to concentrate better? If yes, the evidence does not back it. Save your money. If you are still curious, generic citicoline is the safer, cheaper bet, and branded "Cognizin" is the exact same molecule.

Citicoline and alpha-GPC are both ways of delivering choline, a raw material your brain uses to make the signal acetylcholine. They were built and tested as drugs for failing brains (stroke, brain injury, dementia). Topping up a raw material helps when a factory is running low. A healthy brain is not running low, so adding more raw material does not reliably make it run faster.

That's the general answer. Your stack is different.

Check your whole stack

Before you buy a "focus" supplement with citicoline or alpha-GPC, ask: am I a healthy adult who just wants to concentrate better?

If yes, the evidence does not back it for you. Save your money. The good data is all in older adults with diagnosed cognitive impairment, not healthy focus-seekers. If you are still curious, generic citicoline is the safer, cheaper bet.

Takes less than a minute. No purchase needed.

The Protocol

If you are going to take one

Who / Goal	Dose	Form	Notes
Healthy adult (focus)	No evidence-based dose	—	Benefit unproven; this is the main reason people buy it
Citicoline (cognitive support, older/impaired)	500 mg/day (one capsule)	Generic citicoline	Cleaner safety profile, no stroke signal
Alpha-GPC (MCI/dementia, supervised)	1200 mg/day, split (400 mg x3)	Oral choline alfoscerate	Strongest as a donepezil add-on under medical care

Forms

Citicoline (generic)

>90% absorbed

Cleaner safety. The sensible default if you must choose one.

~£12-20/month

Citicoline (Cognizin)

identical molecule

Same compound as generic. The premium buys a trademark, not better absorption.

~£20-35/month

Alpha-GPC (oral)

raises choline more

Better cognition data in impaired older adults. Carries the stroke-risk question.

~£15-30/month

Absorption tips: Both are well-absorbed orally, with or without food. There is no clever timing or stacking trick that turns either into a healthy-adult focus aid. The limit is not absorption. It is that the benefit was never shown in healthy people to begin with.

Safety & Interactions

Take this, watch for this

Alpha-GPC and stroke risk

Large observational claims data link chronic alpha-GPC use to higher subsequent stroke risk. It is not a randomized trial and is plausibly confounded, since alpha-GPC is prescribed to people who already have vascular disease. It is not proof. But it is a real reason a healthy person should not take alpha-GPC purely for focus.

Cholinergic / anticholinergic medications

Both are cholinergic precursors. Theoretical additive or opposing effect with cholinergic drugs. Speak to a clinician if you take these.

General tolerability

Both are generally well tolerated. Infrequent GI upset, headache, or (citicoline) insomnia. No formal upper limit set for either. Trial ceilings: citicoline 2000 mg/day, alpha-GPC 1200 mg/day. Insufficient safety data in pregnancy or breastfeeding.

Conviction

Low

Low for the marketed healthy-adult focus claim, for both compounds. The one place the evidence is genuinely better is alpha-GPC in diagnosed dementia or mild cognitive impairment, where it earns a moderate rating, tempered by industry funding and a single research group doing much of the work.

What would change this

A double-blind, placebo-controlled trial of at least 200 cognitively healthy adults aged 18-45, randomized to citicoline 500 mg/day, alpha-GPC 600-1200 mg/day, or placebo for at least 8 weeks, measuring a real attention or working-memory task (not a dementia scale, not a single dose), independently funded, showing a meaningful difference, would move the healthy-adult focus verdict up. For the alpha-GPC stroke question, a study that controls for who already had vascular disease would settle whether the risk is real or just confounding.

Worth Your Money?

Weekly costRoughly £3-7 per week at an evidence-based dose (one citicoline capsule a day, or split alpha-GPC).

Worth it ifYou are an older adult with diagnosed cognitive impairment working with a clinician, and alpha-GPC is part of that plan.

Lower priority ifYou are a healthy adult wanting focus. Your next £20 is almost certainly better spent on sleep, training consistency, or simply caffeine plus L-theanine, which has stronger focus evidence.

Skip

Go Deeper

Want to stop wasting money on supplements that don't work? The Verdict reviews one every week, free.

Get the free weekly review

Claims vs Evidence — See What the Research Found

What People Claim

"Your brain runs on acetylcholine. These supplements deliver the choline your brain needs to make it, so more choline means sharper focus, better memory, and more brain energy."

Both have real clinical pedigrees, which is what makes the pitch persuasive. Citicoline was developed as a stroke and brain-injury drug. Alpha-GPC has been trialed in Alzheimer's as an add-on to prescription drugs. Alpha-GPC gets a second pitch in the gym for power output and growth hormone. The industry borrows that clinical credibility and points it at a healthy person who wants to lock in at a desk.

What the Evidence Actually Shows

Claim	Strength	Reality
Healthy-adult focus (citicoline)	WEAK	One modest 500 mg memory trial in healthy older adults, likely industry-linked. No convergent data.
Healthy-adult focus (alpha-GPC)	WEAK	Two or three small, single-dose, surrogate-endpoint studies.
Dementia / vascular decline (citicoline)	WEAK	An aged Cochrane review found a modest signal; the big rigorous trials were null.
Dementia / MCI (alpha-GPC)	MODERATE	A 261-patient Alzheimer's trial plus the ASCOMALVA donepezil add-on series. The best evidence sits here.
Alpha-GPC vs citicoline head-to-head	EMERGING	A 2025 meta-analysis put alpha-GPC ahead on a global dementia scale, but not on memory or word fluency.
Acute stroke / brain-injury recovery	DEBUNKED	The two big clean trials (COBRIT, ICTUS) found no benefit over placebo.
Alpha-GPC for power / growth hormone	WEAK	No qualifying human trial in this evidence base; the claim rests on small industry studies.

The Full Picture — Mechanism, Debate & Nuance

How It Works

Both deliver choline, by different routes. Citicoline splits into cytidine and choline in the gut, both cross into the brain, and cells rebuild them into membrane material. Alpha-GPC is a more direct route to acetylcholine and, head-to-head, raises free choline in the blood more than citicoline does.

Here is the catch the marketing skips: raising a raw material is not the same as raising function. A healthy brain is not generally short of choline. Both clearly move a biochemical number. Whether that becomes a sharper afternoon in someone whose system is already intact is exactly the gap the trials keep failing to close. A higher choline reading is a chart, not a clearer head.

The Debate

Cochrane 2005: citicoline modestly helps memory in elderly with chronic cerebral disorders.

COBRIT 2012 (N=1213): citicoline no better than placebo in brain injury.

Why they disagree: population and rigor. The signal lives in chronic vascular decline; the large, clean, independent trial was flat.

Jin 2025: alpha-GPC beats citicoline on a global dementia score.

Same analysis: no alpha-GPC advantage on memory or word fluency.

Why they disagree: endpoint selection. "Better" depends entirely on which scale you read.

Honest Limitations

Population transfer

Lab studied dementia, stroke, and brain injury. Reality is a healthy person buying a focus stack. Far less benefit than the trial headlines suggest, because the trial populations are not you.

Endpoint mismatch

Lab used clinician-rated dementia scales over months. Reality is wanting a sharper Tuesday afternoon. The acute focus people want is the least-studied outcome of all.

Funding and group concentration

The flagship alpha-GPC trial was industry-funded, the add-on series came from one research group, and the large, independent, rigorous trials are the ones that came back null.

The Nuance

If you want choline from food, eggs, liver, and soy supply it, but that is a nutrition point, not a focus claim. Generic citicoline at £12-20/month is the same molecule as branded Cognizin at £20-35/month. Where money goes further first for a healthy adult: sleep, training consistency, and protein, all of which have stronger ground under them than a focus pill.

What doesn't work

"More choline means sharper focus in a healthy brain." A non-deficient brain is not choline-limited.
"They help you recover from a concussion or stroke." The big rigorous trials were null.
"Alpha-GPC boosts power and growth hormone." No qualifying human trial here; it rests on small industry studies.
"Branded Cognizin is better than generic citicoline." Identical molecule.

Sources

Jin et al. (2025). Choline alphoscerate vs citicoline in dementia: systematic review and meta-analysis. Front Neurol. Alpha-GPC favored on global scale, not all cognitive endpoints. (PMID 41426989)
Fioravanti & Yanagi (2005). CDP-choline for cognitive/behavioural disturbances in the elderly. Cochrane Database Syst Rev. Modest, aged signal. (PMID 15846601)
Zafonte et al. (COBRIT, 2012). Citicoline 2000 mg/day in traumatic brain injury, N=1213. JAMA. No benefit vs placebo. (PMID 23168823)
De Jesus Moreno (2003). Choline alfoscerate 1200 mg/day in mild-moderate Alzheimer's, N=261. Clin Ther. Cognitive improvement; Italfarmaco-funded. (PMID 12637119)
Amenta et al. (ASCOMALVA, 2014). Donepezil + alpha-GPC in Alzheimer's. J Neurol Sci. Slowed decline. (PMID 24898643)
Nakazaki et al. (2021). Citicoline 500 mg/day, memory in healthy older adults, N~100. Modest gain; likely industry-linked. (PMID 33978188)
Marcus et al. (2024). Acute alpha-GPC and cognitive performance in healthy men. Small, single-dose. (PMID 39683633)
Lee SH et al. (2021). L-alpha glycerylphosphorylcholine and subsequent stroke risk, Korean national cohort. JAMA Netw Open. Observational association with higher stroke risk.